Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

Reshma Ramachandran

Biographic Data

ID7230834
NAMEReshma Ramachandran
GIVEN NAMESReshma
FAMILY NAMERamachandran
SIGNATURERAMACHANDRAN R
AFFILIATIONSYale University
ORCID0000-0003-3845-3606
VERIFIEDYes
TOTAL WORKS8
TOTAL CITATIONS0
WORKS AS AUTHOR6
WORKS AS EDITOR2
FIRST PUBLICATION YEAR2021
LATEST PUBLICATION YEAR2025
H-INDEX0
  • Public Health Implications of Legal Challenges to the FDA’s Regulation of Laboratory-Developed Tests

    Open Access•Kushal T Kadakia, James Stirling Ro et al.•ARTICLE•JAMA Health Forum•2025

    The case of LDTs illustrates the challenges the FDA faces when adapting regulatory frameworks in response to emerging health technologies. The outcomes of recent reforms and litigation carry substantial public health implications for both diagnostic technologies and the FDA's broader regulatory remit

  • Online Advertising of Compounded Glucagon-Like Peptide-1 Receptor Agonists

    Open Access•Ashwin K Chetty, Mahima Chillakanti et al.•ARTICLE•JAMA Health Forum•2025

    This cross-sectional study evaluates the quality and accuracy of information presented on websites that sell compounded glucagon-like peptide-1 receptor agonists

  • Association of Covid-19 infection and Covid-19 vaccination with idiopathic sudden sensorineural hearing loss in Malaysia

    Open Access•Nur Syafiqah A Rahim, Nur Sabrina Abdul Rahim et al.•ARTICLE•BMC Public Health•2025

    This study provides significant insights into the intricate correlation between ISSNHL, COVID-19 infection, and vaccination. The recognized hazard linked to infection emphasizes the significance of monitoring auditory health in COVID-19 patients

  • Effectiveness of Covid-19 mRNA vaccine in preventing infection against Omicron strain

    Open Access•Yui Yumiya, Kenya Kawanishi et al.•EDITOR•ARTICLE•PLOS Global Public Health•2024

    Background and purpose Despite the widespread adoption of various preventive measures since the spread of COVID-19, there remains a lack of consensus on universally acknowledged best practices. However, the significance of vaccination has risen to prominence as a paramount preventive strategy. Numerous investigations have demonstrated vaccine effectiveness against the omicron strain in severe disease and symptomatic disease, however, the scope of…

  • User-experience testing of an evidence-to-decision framework for selecting essential medicines

    Open Access•Thomas Piggott, Lorenzo Moja et al.•EDITOR•ARTICLE•PLOS Global Public Health•2024

    Essential medicine lists (EMLs) are important medicine prioritization tools used by the World Health Organization (WHO) EML and over 130 countries. The criteria used by WHO’s Expert Committee on the Selection and Use of Essential Medicines has parallels to the GRADE Evidence-to-Decision (EtD) frameworks. In this study, we explored the EtD frameworks and a visual abstract as adjunctive tools to strengthen the integrate evidence and improve the tra…

  • Extending the US Food and Drug Administration’s Postmarket Authorities

    Open Access•Holly Fernandez Lynch, Rachel E Sachs et al.•ARTICLE•JAMA Health Forum•2023

    Under current FDA approaches to drug approval, patients, clinicians, and payers may be left with little confidence about a drug's benefit not only when it first enters the market but also for an extended period thereafter. If policy makers continue to favor earlier market access over evidentiary certainty, flexible approvals must be matched by more expansive use of postmarket safeguards, an approach possible within the FDA's existing legal author…

  • Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017

    Open Access•Joshua J Skydel, Alexander C Egilman et al.•ARTICLE•JAMA Health Forum•2022

    The findings of this cross-sectional study indicate that most of the drugs granted FDA accelerated approval for original indications from 2012 to 2017 lacked confirmatory trials evaluating clinical outcomes to support conversion to standard approval. Automatic coverage mandates produced substantial CMS spending for drugs with unproven clinical benefits

  • An Unnecessary Gift for Covid-19 Vaccines and Therapeutics

    Reshma Ramachandran, Ravi Gupta et al.•ARTICLE•American Journal of Public Health•2021

    An Unnecessary Gift for COVID-19 Vaccines and Therapeutics: The Medical Countermeasure Priority Review Voucher Reshma Ramachandran MD, MPP, Ravi Gupta MD, and Jing Luo MD, MPH Affiliation Reshma Ramachandran is with the National Clinician Scholars Program, Yale School of Medicine, New Haven, CT, and the Veterans Affairs Connecticut Healthcare System, West Haven, CT. Ravi Gupta is with the National Clinician Scholars Program, University of Pennsyl…

No prominent works on this page.

  • An Unnecessary Gift for Covid-19 Vaccines and Therapeutics

    Reshma Ramachandran, Ravi Gupta et al.•ARTICLE•American Journal of Public Health•2021

    An Unnecessary Gift for COVID-19 Vaccines and Therapeutics: The Medical Countermeasure Priority Review Voucher Reshma Ramachandran MD, MPP, Ravi Gupta MD, and Jing Luo MD, MPH Affiliation Reshma Ramachandran is with the National Clinician Scholars Program, Yale School of Medicine, New Haven, CT, and the Veterans Affairs Connecticut Healthcare System, West Haven, CT. Ravi Gupta is with the National Clinician Scholars Program, University of Pennsyl…

  • Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017

    Open Access•Joshua J Skydel, Alexander C Egilman et al.•ARTICLE•JAMA Health Forum•2022

    The findings of this cross-sectional study indicate that most of the drugs granted FDA accelerated approval for original indications from 2012 to 2017 lacked confirmatory trials evaluating clinical outcomes to support conversion to standard approval. Automatic coverage mandates produced substantial CMS spending for drugs with unproven clinical benefits

  • Extending the US Food and Drug Administration’s Postmarket Authorities

    Open Access•Holly Fernandez Lynch, Rachel E Sachs et al.•ARTICLE•JAMA Health Forum•2023

    Under current FDA approaches to drug approval, patients, clinicians, and payers may be left with little confidence about a drug's benefit not only when it first enters the market but also for an extended period thereafter. If policy makers continue to favor earlier market access over evidentiary certainty, flexible approvals must be matched by more expansive use of postmarket safeguards, an approach possible within the FDA's existing legal author…

  • Effectiveness of Covid-19 mRNA vaccine in preventing infection against Omicron strain

    Open Access•Yui Yumiya, Kenya Kawanishi et al.•EDITOR•ARTICLE•PLOS Global Public Health•2024

    Background and purpose Despite the widespread adoption of various preventive measures since the spread of COVID-19, there remains a lack of consensus on universally acknowledged best practices. However, the significance of vaccination has risen to prominence as a paramount preventive strategy. Numerous investigations have demonstrated vaccine effectiveness against the omicron strain in severe disease and symptomatic disease, however, the scope of…

  • User-experience testing of an evidence-to-decision framework for selecting essential medicines

    Open Access•Thomas Piggott, Lorenzo Moja et al.•EDITOR•ARTICLE•PLOS Global Public Health•2024

    Essential medicine lists (EMLs) are important medicine prioritization tools used by the World Health Organization (WHO) EML and over 130 countries. The criteria used by WHO’s Expert Committee on the Selection and Use of Essential Medicines has parallels to the GRADE Evidence-to-Decision (EtD) frameworks. In this study, we explored the EtD frameworks and a visual abstract as adjunctive tools to strengthen the integrate evidence and improve the tra…

  • Public Health Implications of Legal Challenges to the FDA’s Regulation of Laboratory-Developed Tests

    Open Access•Kushal T Kadakia, James Stirling Ro et al.•ARTICLE•JAMA Health Forum•2025

    The case of LDTs illustrates the challenges the FDA faces when adapting regulatory frameworks in response to emerging health technologies. The outcomes of recent reforms and litigation carry substantial public health implications for both diagnostic technologies and the FDA's broader regulatory remit

  • Online Advertising of Compounded Glucagon-Like Peptide-1 Receptor Agonists

    Open Access•Ashwin K Chetty, Mahima Chillakanti et al.•ARTICLE•JAMA Health Forum•2025

    This cross-sectional study evaluates the quality and accuracy of information presented on websites that sell compounded glucagon-like peptide-1 receptor agonists

  • Association of Covid-19 infection and Covid-19 vaccination with idiopathic sudden sensorineural hearing loss in Malaysia

    Open Access•Nur Syafiqah A Rahim, Nur Sabrina Abdul Rahim et al.•ARTICLE•BMC Public Health•2025

    This study provides significant insights into the intricate correlation between ISSNHL, COVID-19 infection, and vaccination. The recognized hazard linked to infection emphasizes the significance of monitoring auditory health in COVID-19 patients

Medicine (6 works) · Business (3 works) · Disease (3 works) · Food and drug administration (3 works) · Health Systems, Economic Evaluations, Quality of Life (3 works) · Biomedical Ethics and Regulation (2 works) · Computer Science (2 works) · COVID-19 Clinical Research Studies (2 works) · Drug (2 works) · Drug approval (2 works)

Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae